Current status of thalidomide and its role in the treatment of metastatic prostate cancer

被引：24
作者：
Macpherson, GR [1 ]
Franks, M [1 ]
Tomoaia-Cotisel, A [1 ]
Ando, Y [1 ]
Price, DK [1 ]
Figg, WD [1 ]
机构：
[1] NCI, Mol Pharmacol Sect, Div Clin Sci, Canc Therapeut Branch,Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2003年 / 46卷
关键词：
thalidomide; prostate; prostate cancer;
D O I：
10.1016/S1040-8428(03)00064-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the discovery of its anti-angiogenic properties and despite its tragic history, thalidomide has re-surfaced in the field of oncology. Concurrent with its evaluation in various clinical trials for cancer, thalidomide's mechanism of action is sought and new analogues with improved efficacy and pharmacological profile are emerging. This review is a critical evaluation of thalidomide metabolism, molecular targets, anti-angiogenic activity and clinical efficacy with an emphasis on metastatic prostate cancer. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码：S49 / S57
页数：9
相关论文
共 92 条
  • [1] Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide
    Ando, L
    Price, DK
    Dahut, WL
    Cox, MC
    Reed, E
    Figg, WD
    [J]. CANCER BIOLOGY & THERAPY, 2002, 1 (06) : 669 - 673
  • [2] Ando Y, 2002, CLIN CANCER RES, V8, P1964
  • [3] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    Barlogie, B
    Desikan, R
    Eddlemon, P
    Spencer, T
    Zeldis, J
    Munshi, N
    Badros, A
    Zangari, M
    Anaissie, E
    Epstein, J
    Shaughnessy, J
    Ayers, D
    Spoon, D
    Tricot, G
    [J]. BLOOD, 2001, 98 (02) : 492 - 494
  • [4] Assessment of the vascularization in prostatic carcinoma: A morphometric investigation
    Barth, PJ
    Weingartner, K
    Kohler, HH
    Bittinger, A
    [J]. HUMAN PATHOLOGY, 1996, 27 (12) : 1306 - 1310
  • [5] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
    Bauer, KS
    Dixon, SC
    Figg, WD
    [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) : 1827 - 1834
  • [6] Factors promoting tumor angiogenesis
    Beckner, ME
    [J]. CANCER INVESTIGATION, 1999, 17 (08) : 594 - 623
  • [7] CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
    Bettencourt, MC
    Bauer, JJ
    Sesterhenn, IA
    Connelly, RR
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 1998, 160 (02) : 459 - 465
  • [8] Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
    Bostwick, DG
    Wheeler, TM
    Blute, M
    Barrett, DM
    MacLennan, GT
    Sebo, TJ
    Scardino, PT
    Humphrey, PA
    Hudson, MA
    Fradet, Y
    Miller, GJ
    Crawford, ED
    Blumenstein, BA
    Mahran, HE
    Miles, BJ
    [J]. UROLOGY, 1996, 48 (01) : 47 - 57
  • [9] TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450
    BRAUN, AG
    HARDING, FA
    WEINREB, SL
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 82 (01) : 175 - 179
  • [10] TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES
    BRAUN, AG
    WEINREB, SL
    [J]. TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, 1985, 5 (03): : 149 - 158
12345678910